Latest Relmada Therapeutics Inc. Stories

Relmada Therapeutics retains Brio Financial Group and GBH CPAs, PC to prepare the Company for its planned Public Listing. NEW YORK, May 20, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that has retained Brio Financial Group ("Brio") and GBH CPAs, PC ("GBH") as financial reporting consultant and audit firms, respectively. This important development is in line with the plan to...

Relmada Therapeutics announces the approval of its CTA (Clinical Trial Authorization) by the MHRA (Medicines and Healthcare products Regulatory Agency) in the United Kingdom to conduct a Phase 1 pharmacokinetic study with LevoCap ER. BLUE BELL, Pa., March 4, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the approval of the application of a Clinical Trial Authorization (CTA) that...

BLUE BELL, Pa., Jan. 4, 2013 /PRNewswire/ -- Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Sergio Traversa, the company's Chief Executive Officer, will be presenting at the Biotech Showcase in San Francisco on Tuesday, January 8, 2013 at 1:45 PM Pacific Time. The presentation will include an overview of Relmada business and an update on the ongoing development programs of LevoCap, d-methadone,...

BLUE BELL, Pa., July 24, 2012 /PRNewswire/ -- Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain today announced the initial closing of $3 million in gross proceeds in a Series A financing for which Laidlaw & Company (UK) Ltd. is the exclusive placement agent. Noteholders BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania, as well as, equity investor Wonpung Mulsan Co., Ltd, have converted their...